Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Navlimetostat in Advanced Solid Tumors With MTAP Deletion (MountainTap-5)
NCT07492680Phase 2Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2026
- Primary completion
- Aug 2028
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 2 trial of navlimetostat in solid tumor, sponsored by Bristol Myers Squibb. Started Jul 2026; status: recruiting.
02
Drugs
navlimetostat
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07492680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07492680.